<DOC>
	<DOC>NCT01521494</DOC>
	<brief_summary>To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.</brief_summary>
	<brief_title>PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients age 20 or older, regardless of gender. Receiving stable maintenance hemodialysis 3 times a week. Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start. Patients having history of a pronounced brain / cardiovascular disorder. Patients having severe gastrointestinal disorders. Patients having severe hepatic disorders.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>